Adcetris® (Brentuximab Vedotin)

Brentuximab Vedotin 50mg/Vial Injection — CD30-directed antibody-drug conjugate

Additional information

Composition

Brentuximab Vedotin 50 mg

Manufacturer

Seagen Inc. (Pfizer)

Country

United States

Pack size

1 single-dose vial (50 mg/vial)

Storage

Refrigerate at 2°C to 8°C in original carton, protect from light

Prescription medicine

Supplied only against a valid prescription from a registered medical practitioner.

100% genuine

Sourced from authorised channels

Cold-chain delivery

Temperature-controlled packing

Pan-India delivery

Hospitals, clinics, pharmacies

Licensed distributor

Delhi drug licence holder

Product information

Adcetris® (Brentuximab Vedotin) — CD30-Directed Antibody-Drug Conjugate: A Sourcing Guide for Hospitals and Oncology Centres

Adcetris® (brentuximab vedotin) is a CD30-directed antibody and microtubule inhibitor conjugate. According to its approved US prescribing information, it is indicated for certain patients with classical Hodgkin lymphoma (cHL), systemic anaplastic large cell lymphoma (sALCL), other CD30-expressing peripheral T-cell lymphomas, primary cutaneous ALCL or CD30-expressing mycosis fungoides, and, in combination with lenalidomide and a rituximab product, relapsed or refractory large B-cell lymphoma (LBCL) in defined patient groups. The decision to prescribe Adcetris, including patient selection, combination partners, schedule and monitoring, rests entirely with the treating physician. This page provides sourcing and procurement information for hospitals and pharmacies, not clinical or treatment guidance.

As both a trusted medicine distributor in Delhi and a licensed pharmaceutical distributor in Delhi, A.K. Pharma supplies genuine Adcetris (brentuximab vedotin) 50 mg vials to hospitals, oncology centres and pharmacies across India. Hospital buyers comparing pharmaceutical distribution companies and wholesale pharmaceutical distributors can also browse our full product range and the cancer medicines category. Supply is in bulk/wholesale quantities only.


What is Adcetris (Brentuximab Vedotin)?

Adcetris is an antibody-drug conjugate (ADC) made of three components, as described in the prescribing information: a chimeric IgG1 antibody directed at CD30, the microtubule-disrupting agent monomethyl auristatin E (MMAE), and a protease-cleavable linker that joins them.

How it works, according to the label: CD30 is a protein found on the surface of cells in several lymphomas. The label describes the ADC binding to CD30-expressing cells, being taken into the cell, and releasing MMAE, which disrupts the microtubule network and leads to cell-cycle arrest and cell death.


Indications as Listed in the Approved Label

The current US prescribing information (DailyMed, revised 2025) lists the following. Indications in India and other countries may differ and are defined by each country’s regulator.

  • Previously untreated Stage III or IV classical Hodgkin lymphoma in adults, in combination with doxorubicin, vinblastine and dacarbazine
  • Previously untreated high-risk classical Hodgkin lymphoma in paediatric patients aged 2 years and older, in combination with chemotherapy
  • Classical Hodgkin lymphoma at high risk of relapse or progression as consolidation after autologous stem cell transplant
  • Classical Hodgkin lymphoma after failure of auto-HSCT, or after failure of at least two prior multi-agent regimens in patients who are not auto-HSCT candidates
  • Previously untreated sALCL or other CD30-expressing peripheral T-cell lymphomas, in combination with cyclophosphamide, doxorubicin and prednisone
  • sALCL after failure of at least one prior multi-agent chemotherapy regimen
  • Primary cutaneous ALCL or CD30-expressing mycosis fungoides after prior systemic therapy
  • Relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy in patients not eligible for auto-HSCT or CAR T-cell therapy, in combination with lenalidomide and a rituximab product

Clinical Studies and Evidence

The studies below are summarised as published; they are cited for information about the evidence behind the label and are not a recommendation for any patient.

  • ECHELON-1 (Connors et al., New England Journal of Medicine, 2018) studied brentuximab vedotin with AVD versus ABVD in previously untreated advanced-stage classical Hodgkin lymphoma. Read the publication.
  • ECHELON-2 (Horwitz et al., The Lancet, 2019) studied brentuximab vedotin with CHP versus CHOP in previously untreated CD30-positive peripheral T-cell lymphoma. Read the publication.
  • AETHERA (Moskowitz et al., The Lancet, 2015) studied brentuximab vedotin consolidation after autologous stem cell transplant in Hodgkin lymphoma patients at high risk of relapse. Read the publication.
  • ALCANZA (Prince et al., The Lancet, 2017) studied brentuximab vedotin versus physician’s choice in CD30-expressing cutaneous T-cell lymphoma. Read the publication.
  • ECHELON-3 (Bartlett et al., Journal of Clinical Oncology, 2025) randomised 230 patients with relapsed or refractory diffuse large B-cell lymphoma to brentuximab vedotin plus lenalidomide and rituximab or placebo plus lenalidomide and rituximab. As reported, median overall survival was 13.8 months versus 8.5 months (hazard ratio 0.63; 95% CI 0.45–0.89). Trial results apply to the population studied. ASCO Post summary.

Available Presentation

Presentation Strength Administration
Lyophilised powder in a single-dose vial, individually boxed 50 mg per vial Intravenous infusion after reconstitution and dilution (per prescribing information)

The label states that, after reconstitution with 10.5 mL of Sterile Water for Injection, the concentration is 5 mg/mL. The label also lists weight-based dosing schedules that differ by indication. These must be determined and followed exactly as directed by the treating physician and the approved prescribing information.


Key Benefits for Procurement

  • Genuine, sealed original-pack stock sourced through authorised channels
  • Single-vial presentation that suits hospital pharmacy planning
  • Cold-chain handling of temperature-sensitive biologic stock
  • Batch and expiry details provided on request
  • Documentation support for hospital purchase departments

Who Is This Page For?

This page is written for hospital pharmacists, oncology and haematology department buyers, and pharmacies that source specialty oncology products. Adcetris is administered in a clinical setting under the supervision of an oncologist or haematologist, as described in the prescribing information.


Possible Side Effects Reported in the Label

The prescribing information reports, for monotherapy in adults, that the most common adverse reactions (20% or more) were peripheral neuropathy, fatigue, upper respiratory tract infection, musculoskeletal pain, nausea, diarrhoea, pyrexia, rash and cough. The label carries a boxed warning for progressive multifocal leukoencephalopathy (PML), a JC virus infection that can be fatal. Other warnings listed include infusion reactions and anaphylaxis, hematologic toxicities, serious infections, tumor lysis syndrome, hepatotoxicity, pulmonary toxicity, serious dermatologic reactions, gastrointestinal complications and hyperglycemia. This list is not complete; the full prescribing information governs.


Precautions

  • The label states Adcetris is contraindicated with concomitant bleomycin because of pulmonary toxicity.
  • The label notes the risk of fetal harm and advises effective contraception for people of reproductive potential.
  • Adcetris is described as a hazardous product, so the label directs special handling and disposal procedures.

All use should follow the approved prescribing information and the instructions of the treating physician.


Storage and Handling

Per the label, store vials refrigerated at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light. Hospitals should follow their own hazardous-drug handling policies.


Manufacturer Information

Adcetris was developed by Seagen Inc., now part of Pfizer. A.K. Pharma is a licensed distributor and does not manufacture the product. As one of the pharmaceutical distributors serving Indian hospitals, we source Adcetris through authorised channels and supply it with pack and batch details. Buyers comparing a pharmaceutical wholesale distributors list or a pharma distribution company can verify our credentials on the About Us page.


Related Medicines


Frequently Asked Questions

Is Adcetris available in India?
A.K. Pharma supplies Adcetris (brentuximab vedotin) 50 mg vials to hospitals and pharmacies in India. Contact us for current availability.

What does Adcetris contain?
Brentuximab vedotin, a CD30-directed antibody-drug conjugate, supplied as 50 mg lyophilised powder in a single-dose vial.

Can I order a single vial?
A.K. Pharma is a distributor and supplies bulk/wholesale quantities only, not one or two pieces.

How should Adcetris be stored?
The label states 2°C to 8°C in the original carton, protected from light.

Does A.K. Pharma advise on dosing or suitability?
No. Treatment decisions, including dosing, rest solely with the treating physician and the approved prescribing information.

How do I request a quote?
Call or WhatsApp us, or use the contact details below.


Why Order from A.K. Pharma

  • Licensed pharmaceutical distributor in Delhi with 25+ years in specialty medicines
  • Genuine, original-pack stock
  • Cold-chain handling for temperature-sensitive products
  • Bulk/wholesale supply to hospitals, oncology centres and pharmacies
  • Batch and expiry details on request
  • Dedicated team for hospital procurement queries

Sources and Further Reading


Contact A.K. Pharma for Adcetris Supply

📍 E-2/257A, 2nd Floor, Shastri Nagar, New Delhi 110052
📞 011 4172 6999
📱 WhatsApp: +91 9810034827
🌐 akpharma.in


Disclaimer: This page is intended for informational and sourcing/procurement purposes only and does not constitute medical or clinical advice. A.K. Pharma is a licensed medicine distributor, not a healthcare provider, and does not provide clinical guidance. All treatment decisions, including drug selection and dosing, rest solely with the treating physician and should follow the approved prescribing information.

Hi! 👋 Looking for a medicine? I can help you find it.

Quote Request Form


Quote Request Form